The rival biotechs have been battling for more than a year over patent claims covering treatment methods for epileptic disorders, including a difficult-to-treat condition characterized by long-lasting seizures called status epilepticus (SE). On Tuesday, Ovid filed a new petition urging the US Patent and Trademark Office (USPTO) to review Marinus’ Patent No. 11,110,100, which covers methods for administering Marinus’ Phase 3 candidate ganaxolone to treat SE.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.